CCG-TH35

CCG-TH35 is a potent, small molecule inhibitor of the Rho/MRTF/SRF (Myocardin-related transcription factor/Serum response factor) signaling pathway, representing an optimized analog of the earlier compound CCG-203971. Developed by researchers at the University of Michigan, CCG-TH35 functions by blocking Rho-mediated gene transcription, a process essential for the activation of myofibroblasts and the subsequent deposition of extracellular matrix proteins. This mechanism makes it a promising therapeutic candidate for various fibrotic conditions, including systemic sclerosis (scleroderma) and pulmonary fibrosis. Beyond fibrosis, the Rho/MRTF/SRF axis is a known driver of the epithelial-to-mesenchymal transition (EMT) and cancer cell migration, leading to investigations of CCG-TH35 as an anti-metastatic agent in malignancies such as melanoma.